StreetInsider.com News Articles

Form 10-Q ASTROTECH Corp For: Dec 31

Fri, 13 Feb 2026 08:26:00 -0500

si-local-file:///var/storage/secattach/20260213/25995994.html

Form 10-Q ASTROTECH Corp For: Dec 31

Fri, 13 Feb 2026 08:26:00 -0500

si-local-file:///var/storage/secattach/20260213/25995994.html

Form 8-K ASTROTECH Corp For: Feb 13

Fri, 13 Feb 2026 08:20:00 -0500

si-local-file:///var/storage/secattach/20260213/25995953.html

Form 8-K ASTROTECH Corp For: Feb 13

Fri, 13 Feb 2026 08:20:00 -0500

si-local-file:///var/storage/secattach/20260213/25995953.html

Astrotech Reports Second Quarter of Fiscal Year 2026 Financial Results

Fri, 13 Feb 2026 08:15:00 -0500

AUSTIN, Texas, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the second quarter of fiscal year 2026, which ended December 31, 2025.

Financial Highlights & Recent Developments

Research and development expense was $1,832 thousand, a decline of 25% from the second quarter of fiscal year 2025 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect Tracer 1000 product lines.
Through December 31, 2025, the Company has deployed the TRACER 1000 trace detection system

Astrotech Reports Second Quarter of Fiscal Year 2026 Financial Results

Fri, 13 Feb 2026 08:15:00 -0500

Financial Highlights & Recent Developments

Research and development expense was $1,832 thousand, a decline of 25% from the second quarter of fiscal year 2025 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect Tracer 1000 product lines.
Through December 31, 2025, the Company has deployed the TRACER 1000 trace detection system

Astrotech Reports Second Quarter of Fiscal Year 2026 Financial Results

Fri, 13 Feb 2026 08:15:00 -0500

Financial Highlights & Recent Developments

Research and development expense was $1,832 thousand, a decline of 25% from the second quarter of fiscal year 2025 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect Tracer 1000 product lines.
Through December 31, 2025, the Company has deployed the TRACER 1000 trace detection system

Astrotech Reports Second Quarter of Fiscal Year 2026 Financial Results

Fri, 13 Feb 2026 08:15:00 -0500

Financial Highlights & Recent Developments

Research and development expense was $1,832 thousand, a decline of 25% from the second quarter of fiscal year 2025 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect Tracer 1000 product lines.
Through December 31, 2025, the Company has deployed the TRACER 1000 trace detection system

Form EFFECT ASTROTECH Corp

Mon, 02 Feb 2026 06:08:00 -0500

si-local-file:///var/storage/secattach/20260202/25926540.html

Form EFFECT ASTROTECH Corp

Mon, 02 Feb 2026 06:08:00 -0500

si-local-file:///var/storage/secattach/20260202/25926540.html

Astrotech (ASTC) files $30M mixed shelf

Wed, 28 Jan 2026 17:14:30 -0500

Astrotech (NASDAQ: ASTC) has filed $30,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Warrants

Units

Astrotech (ASTC) files $30M mixed shelf

Wed, 28 Jan 2026 17:14:30 -0500

Astrotech (NASDAQ: ASTC) has filed $30,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Warrants

Units

Form S-3 ASTROTECH Corp

Wed, 28 Jan 2026 17:11:00 -0500

si-local-file:///var/storage/secattach/20260128/25909775.html

Form S-3 ASTROTECH Corp

Wed, 28 Jan 2026 17:11:00 -0500

si-local-file:///var/storage/secattach/20260128/25909775.html

Astrotech subsidiary 1st Detect names David Spada global sales director

Wed, 21 Jan 2026 16:15:09 -0500

Astrotech Corporation (NASDAQ: ASTC) announced that its subsidiary 1st Detect Corporation has appointed David Spada as Director of Global Sales. The appointment aims to expand deployment of the company's TRACER 1000 mass spectrometry-based explosives and narcotics trace detector in international security markets.

Spada brings over a decade of trace detection experience from positions at Implant Sciences, Morpho Detection, and Rapiscan Systems. He previously held roles in product management, strategy, and business development, and was responsible for trace detection sales revenue and strategy for the Americas region.

"David brings extensive industry experience and market knowledge to the 1st Detect team, having been at

Astrotech Subsidiary 1st Detect Appoints Industry Veteran David Spada as Director of Global Sales to Expand Global Reach of TRACER 1000™

Wed, 21 Jan 2026 16:15:00 -0500